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The role of aristolochic acid in the etiology of Balkan endemic nephropathy (BEN) and associated
upper-tract urothelial carcinoma (UTUC) has been recently conﬁrmed. The aim of this study was to
determine apoptosis-related marker(s) speciﬁc for BEN-associated UTUC. Present investigation
included 105 patients with UTUC, 44 from BEN region and 61 control tumors. Altered expression
of Survivin was more often present in BEN UTUC with high grade and solid growth (P < 0.005;
P < 0.05) than in control tumors. Signiﬁcantly lower expression of proapoptotic marker Bax was
found in BEN tumors with high grade, high stage, necrosis, and without metaplastic change
(P < 0.05; 0.05; 0.05; 0.05) compared to control tumors with the same features. Group (BEN-
related/control), stage, growth pattern, and caspase 3 activity were signiﬁcantly associated with
the expression of Bax (P = 0.002, 0.034, 0.047, 0.028, resp.,). This investigation identiﬁes Bax
as speciﬁc marker of BEN-associated UTUC. Decrease of pro-apoptotic protein Bax together with
alteration of Survivin may be indicative for speciﬁc disturbances of intrinsic apoptotic pathway in
UTUC arising in endemic areas.
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1. INTRODUCTION
Balkan endemic nephropathy (BEN) is a chronic tubulointerstitial disease with insidious onset and slow
progression to terminal renal failure. BEN is geographically conﬁned to several rural regions of the Balkans
along the Danube river [1]. In Serbia BEN was described in 1957, and in the last ﬁfty years much was done
to advance the understanding of this disease [2]. BEN is an environmental disease, the result of interplay of
environmental and genetic factors [3, 4]. Several investigators suggested that the disease could result from
prolonged exposure to a multitude of environmental toxicants, such as herbs containing aristolochic acid
(AA) [5, 6], mycotoxins [7], and organic compounds leached from coal deposits [8]. In addition to renal
disease, an increased number of upper tract urothelial carcinoma (UTUC) have been observed in the foci of
BEN [9, 10]. Carcinomas may occur alone or in combination with BEN. Their incidence increases with age
atthetimeofdiagnosisandwithalongersurvivalandishigherinfemales[1,10].Themolecularmechanism
of AA-induced carcinogenesis demonstrated a strong association between DNA adduct formation, mutation
pattern, and tumor development [11, 12]. Our recent investigation detected p53 pathway as the speciﬁcc e l l
cycle marker involved in BEN-related UTUC [13].
Similar to other neoplasms, urothelial cancer initiates and progresses from genetic and epigenetic
events affecting the complex, but delicates molecular interplay of factors that drive the cell to survive and
proliferate or to enter the spiral of programmed cell death. To date, limited number of studies investigated
apoptosis-related markers in patients with UTUC, probably due to the relative rarity of urothelial cancers of
renal pelvis and ureter. Urothelial cancer may resist programmed cell death with altered expression of both
proapoptotic and antiapoptotic proteins [14, 15].
The aims of this study were to evaluate and correlate the expression of apoptotic markers—Survivin,
Bcl-2, Bax, Fas, and caspase 3—with pathological characteristics of UTUC in BEN and control population
and to determine the apoptotic marker(s) which is speciﬁc indicator of BEN-related UTUC.
2. PATIENTS AND METHODS
2.1. Patients Population
We studied 105 consecutive patients with UTUC who had undergone the open type of nephroureterectomy
with removal of bladder cuff as part of the nephroureterectomy procedure. Extended lymphadenectomy
was not routinely performed. All cases of UTUC were diagnosed at the Institute of Pathology, Faculty of
Medicine, Nis Serbia. The analysis included 73 transitional cell carcinomas with pelvic localization and 32
with, ureteral. Patients were divided in two groups: 44 patients were from endemic settlements, the villages
along the South Morava River basin (BEN tumors), and 61 control subjects, residents of rural and city areas
free of BEN.
2.2. Histologic Analysis
The histological sections were processed from tissue ﬁxed in 10% formalin by standard techniques and
stained with haematoxylin and eosin (H&E). H&E-stained slides were used to assess histological grade
( l o wa n dh i g hg r a d e )[ 16], pathologic stage (pT) [17], growth of tumor (papillary/solid), lymphovascular
invasion (LVI), and the presence of necrosis and metaplastic changes (squamous or glandular) within
the tumor. The authors compared low-stage nonmuscle invasive tumors (pTa-pT1) and high-stage muscle
invasive (pT2-pT4) tumors [18]. The presence of tumor necrosis was evaluated based on microscopic
examination of tumor. According to the WHO criteria for the diagnosis of histological variants of urothelial
cancer, squamous differentiation was deﬁned as the presence of intercellular bridges or keratinization
[16]. The conventional criteria for squamous metaplastic change in UTUC include abundant eosinophilic
cytoplasm and large oval nuclei with an open chromatin pattern and prominent nucleoli. Glandular
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differentiation was deﬁned as the presence of true glandular spaces and gland-like lumina within tumor cell
nests.
2.3. Immunohistochemistry and Scoring
Tumors were analyzed using the mouse monoclonal antibodies against Bcl-2 (Clone 124, M 0887/Dako),
Survivin (FL-142: sc-10811/Santa Cruz Biotechnology), Bax (Code A 3533/Dako), Fas (C-20: sc-
715/Santa Cruz Biotechnology), and caspase 3 cleaved (ACR 229 A, B, C/Biocare Medical) at dilution
of 1:50, 1:500, 1:1000, 1:100, 1:200, respectively, and a standard avidin-biotin immunoperoxidase
complexes detection system, according to the manufacturer’s protocol (Dako LSAB2R system-HRP).
Before quantifying the immunohistochemical results, the technique quality was assessed, and those areas
with greater positivity were selected, avoiding peripheral area measurement, necrosis, or artifact. Slides
were reviewed independently by three investigators (LJV, SS, ARP). Interobserver discrepancies were
resolved using a double-headed microscope. Nuclear expression was recorded for Survivin, membranous
and cytoplasmic for Fas [19], and cytoplasmic for Bax, Bcl-2, and caspase 3.
Immunohistochemical reaction was scored as follows: negative if ≤10% of cells were stained and
positive if ≥10% were stained. Cytoplasmic staining intensity was scored using a scale of 0 to 3 (0, no
staining; 1, weak; 2, moderate; 3, intense). All markers were placed in one of two categories, altered or not
altered (normal). Nuclear Survivin immunoreactivity was considered altered when samples demonstrated
at least 10% nuclear reactivity [20]. Bcl-2, Bax, and Fas immunoreactivity was considered altered when
samples demonstrated positivity in >10% of tumor cells with an intensity of 2 or 3. Cleaved caspase 3
index was calculated as number of positive cells ×100 per total number of cells in ten random high-power
ﬁelds (x400) in each tumor. This index was established by counting at least 2000 cells in ﬁelds distant from
necrotic areas [21, 22].
2.4. Statistical Analysis
For purposes of analysis, pathological tumor stage (low versus high), grade (low versus high), growth
pattern (papillary versus solid), LVI (yes versus no), and clinical parameters—sex (M versus F), localization
(pelvis versus ureter)—were evaluated as dichotomized variables. The Fisher’s exact test and the χ2
test were used to estimate the expression of Survivin, Bcl-2, Bax, and Fas in regard to pathological
parameters (stage, grade, growth, lymphovascular invasion, necrosis, metaplastic differentiation) of tumors
and Mann-Whitney U test in evaluation of caspase 3 index with investigated parameters. Spearman’s
non-parametric coefﬁcients and Pearson’s correlation coefﬁcients were calculated to estimate correlations
between pathological characteristics and expression of apoptotic markers. In order to determine the
inﬂuence of each variable on expression of apoptotic biomarkers, a multivariate binary logistic regression
was performed. Odds ratios (OR) were estimated using the 95% conﬁdence interval (CI), as well as linear
regression model for continuous variable—cleaved caspase 3 index. The result was considered statistically
signiﬁcant if P < 0.05. All analyses were performed with the SPSS statistical package (SPSS version 10.0
for Windows).
3. RESULTS
3.1. Clinical Features in UUC
The age in 105 patients with UTUC ranged from 32 to 87 years, with a mean age of 64.5 ± 8.8 years for
tumors in BEN regions and 64.2 ± 11 years for control tumors. There were 22 male (50%) and 22 female
(50%) patients in BEN-associated UTUC group with ratio M:F = 1:1, while in the control group there
were 37 men (61%) and 24 women (39%), with ratio M:F = 1.5:1. Tumor localization was more frequent
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FIGURE 1: The representative immunohistochemical staining of apoptotic markers in BEN-associated
urothelial carcinoma, with strong nuclear Survivin activity in high grade (a) and tumors with solid growth (b),
diffuse Bax cytoplasm expression (c), membranous Fas staining in nonmetaplastic BEN-related tumors (d).
Rarely Bcl-2 positive tumor cells (e). Caspase 3 expression in a high-grade tumor (f) (original magniﬁcation:
x400).
on the left side in both BEN and control UTUC, however, without statistical difference between these two
groups (27/17 versus 37/24).
3.2. Immunohistochemical Evaluation of Apoptosis-Related Biomarkers and
Association with Pathological Characteristics in BEN and Control UTUC
The immunohistochemical staining of Survivin, Bcl-2, Bax, and Fas was detected in 81 (77.1%), 34
(32.4%), 79 (75.2%), and 73 (69.5%) UTUC, respectively. Apoptotic markers—Survivin, Bcl-2, Bax, and
Fas—were altered in 55 (52.4%), 16 (15.2%), 61 (58.1%), 45 (42.9%) UTUC, respectively. The mean
caspase 3 labeling index was 2.5 ± 7.4% (SD). Tables 1 and 2 displays relationships between conventional
pathological parameters and immunohistochemical staining of Survivin, Bcl-2, Bax, Fas, and caspase 3 in
BEN and control UTUC. Nuclear immunostaining of Survivin was signiﬁcantly higher in BEN tumors with
high grade and solid growth than in those of the control group (χ2 = 4.96, P < 0.005; χ2 = 4.0, P < 0.05,
resp.) (Figures 1(a) and 1(b) ). Immunostaining of the proapoptotic marker Bax was lower in BEN tumors
(Figure 1(c) ) with the high grade, high stage, with the presence of necrosis, and without metaplastic
differentiation (χ2 = 5.73, P < 0.05; χ2 = 4.84, P < 0.05; χ2 = 4.13, P < 0.05; χ2 = 3.85, P < 0.05,
resp.) than in control tumors with the same morphological characteristics. Moreover, BEN UTUC without
metaplastic change had higher expression of Fas (Figure 1(d) ) than control tumors (χ2 = 5.38, P < 0.05).
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TABLE 1: Association of antiapoptotic biomarkers expression with pathological characteristics of UTUC.
UUC N
Altered expression of biomarker
Survivin P < Bcl-2 P <
Low grade N.S. N.S.
BEN 16 5 3
Control 25 12 4
High grade 0.05 N.S.
BEN 28 21 4
Control 36 17 5
Low stage N.S. N.S.
BEN 17 10 2
Control 19 8 4
High stage N.S. N.S.
BEN 27 16 5
Control 42 21 5
Papillary growth N.S. N.S.
BEN 12 4 2
Control 27 14 5
Solid growth 0.05 N.S.
BEN 32 22 5
Control 34 15 4
LV invasion: yes N.S. N.S.
BEN 10 8 1
Control 20 10 2
Necrosis: yes N.S. N.S.
BEN 19 12 4
Control 25 12 2
Nonmetaplastic N.S. N.S.
BEN 34 18 4
Control 48 22 5
Metaplastic N.S. N.S.
BEN 10 8 3
Control 13 7 3
χ2 test was performed.
N.S.: no signiﬁcance.
The expression of Bcl-2 and cleaved caspase 3 were not signiﬁcantly associated with the phenotypic
characteristics of BEN-associated UTUC (Figures 1(e) and 1(f) ) and control UTUC.
3.3. Comparison of Apoptosis-Related Biomarkers in BEN and Control UTUC
Comparing apoptosis-related biomarkers and group, the signiﬁcant difference in Bax expression was
detected (Table 3). BEN tumors had less frequent alteration of Bax than control tumors (20/24 (45.5%)
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TABLE 2: Association of proapoptotic biomarkers expression with pathological characteristics of UTUC.
UUC N
Altered expression of biomarker
Bax P < Fas P < Casp3 index∗ P <
Low grade N.S. N.S. N.S
BEN 16 9 7 6.7 ± 15.8
Control 25 16 8 2 ± 5.3
High grade 0.05 N.S. N.S.
BEN 28 11 16 1.7 ± 2.7
Control 36 25 14 1.7 ± 4.6
Low stage N.S. N.S. N.S.
BEN 17 10 9 2.9 ± 7.5
Control 19 14 7 2.6 ± 6.7
High stage 0.05 N.S. N.S.
BEN 27 10 14 3.9 ± 11.2
Control 42 27 15 1.5 ± 3.9
Papillary growth N.S. N.S. N.S.
BEN 12 4 3 4.2 ± 8.8
Control 27 18 8 3.2 ± 7.1
Solid growth N.S. N.S. N.S.
BEN 32 16 20 3.2 ± 10.4
Control 34 23 14 0.8 ± 1
LV invasion: yes N.S. N.S. N.S.
BEN 10 4 6 7 ± 17.9
Control 20 15 7 1 ± 1.3
Necrosis: yes 0.05 N.S. N.S.
BEN 19 7 10 1.9 ± 2.8
Control 25 17 11 1 ± 1
Nonmetaplastic 0.05 0.05 N.S.
BEN 34 16 17 3.6 ± 11.1
Control 48 33 12 1.7 ± 4.3
Metaplastic N.S. N.S.
BEN 10 4 6 3.2 ± 4
Control 13 8 10 2.6 ± 6.8
χ2 test was performed.
∗Mann Whitney U test was performed.
N.S.: no signiﬁcance.
versus 41/20 (67.2%), χ2 = 4.92, P < 0.05). In contrast to this marker, the expression of Survivin, Bcl-2,
Fas, and caspase 3 was not signiﬁcantly associated with the groups (Table 3).
A possible correlation between Survivin, Bcl-2, Bax, Fas, and caspase 3 activity and standard
pathological features and group was also investigated. Spearman’s coefﬁcient of correlation showed that
Survivin correlates with the Bcl-2 and Fas (correlation coefﬁcient ρ =0.192, 0.248, P =0.050, 0.011), Bcl-
2 with the expression of Bax, and Fas (correlation coefﬁcient ρ = 0.199, 0.275, P = 0.042, 0.004, resp.),
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TABLE 3: Expression of apoptosis-related markers in UTUC associated with BEN and in control UTUC.
Molecular marker
BEN (N = 44) Control (N = 61)
P <
Expression N (%)
Survivin N.S.
Not altered 18 (40.9) 32 (52.5)
Altered 26 (59.1) 29 (47.5)
Bcl-2 N.S.
Not altered 37 (84.1) 52 (85.2)
Altered 7 (15.9) 9 (14.8)
Bax 0.05
Not altered 24 (54.5) 20 (32.8)
Altered 20 (45.5) 41 (67.2)
Fas N.S.
Not altered 21 (47.7) 39 (63.9)
Altered 23 (52.3) 22 (36.1)
Caspase 3∗ N.S.
X ± SD 3.5 ± 9.9 1.9 ± 4.9
χ2 test was performed
∗Mann Whitney U test was performed
N.S.: no signiﬁcance.
Bax correlates with the group (correlation coefﬁcient ρ = 0.218, P = 0.026), and Fas activity with the
localization, growth, and metaplastic change (correlation coefﬁcient ρ = 0.263, 0.228, 0.286, P = 0.007,
0.020, 0.003, resp.). Index of caspase 3 activity is in correlation with the expression of Survivin, Bcl-2, Bax,
and Fas (Pearson’s correlation coefﬁcient r = 0.192, 0.522, 0.200, 0.280; P = 0.050, 0.0001, 0.040, 0.004,
resp.).
In addition, multistep logistic regression model which included investigated apoptotic markers
(Survivin, Bcl-2, Bax, and Fas), group, pathological characteristics, gender, and localization, showed that
the proapoptotic marker Fas had prominent inﬂuence to the expression of Survivin (Wald = 5.841 P =
0.016), caspase 3 index to the expression of Bcl-2 (Wald = 10.736 P = 0.001) and group, stage, growth
and caspase 3 index had prominent inﬂuence to expression of Bax (Wald = 9.919 P = 0.002; Wald =
4.484 P = 0.034; Wald = 3.940 P = 0.047; Wald = 4.841 P = 0.028), while localization, metaplastic
change in UTUC, and caspase 3 index were signiﬁcantly associated with the proapoptotic marker Fas (Wald
=6.102 P =0.013;Wald=4.138 P =0.042;Wald=5.622 P =0.018,Table 4).Inlinearregressionmodel
which detected inﬂuence of investigated parameters to caspase 3 activity, we found that differentiation
of UTUC and Bcl-2 had signiﬁcant inﬂuence (t =− 2.243 P = 0.027; t = 5.665 P = 0.0001). Between
investigated apoptotic markers, only Bax was speciﬁc indicator of group. UTUC from BEN region was
associated with reduction of this proapoptotic marker.
4. DISCUSSION
Approximately 5% of urothelial tumors arise in the upper urinary tract [23]. Although both derived from
urothelial cells, recent studies established certain discrepancies between transitional cell carcinoma (TCC)
of upper and lower urothelium in relation to the mechanisms of carcinogenesis, biological behavior, and
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TABLE 4: Multivariate logistic regression and linear regression analysis of all UTUC.
Logistic
regresion
Model
Dependent
variable
Predictor B S.E. Wald Sig. Exp(B)
95.0% C.I.
for EXP(B)
sig. Lower Upper
0.014 Survivin Fas −0.996 0.412 5.841 0.016 0.369 0.165 0.828
Constant 0.659 0.318 4.296 0.038 1.933
0.0001 Bcl-2 Caspase 3 0.362 0.111 10.736 0.001 1.437 1.157 1.784
Constant −2.667 0.421 40.215 0.000 0.069
0.0001 Bax Group 1.542 0.490 9.919 0.002 4.673 1.790 12.199
Stage 1.125 0.531 4.484 0.034 3.080 1.087 8.723
Growth −1.031 0.519 3.940 0.047 0.357 0.129 0.987
Caspase 3 0.326 0.148 4.841 0.028 1.385 1.036 1.851
Constant −0.945 0.445 4.500 0.034 0.389
0.0001 Fas Pelvis/Ureter −1.312 0.531 6.102 0.013 0.269 0.095 0.763
Metaplastic −1.215 0.597 4.138 0.042 0.297 0.092 0.957
Caspase 3 0.318 0.134 5.622 0.018 1.374 1.057 1.787
Constant 1.793 0.722 6.160 0.013 6.008
linear
regresion
model
Dependent
variable
Predictor B S.E. Standardized coefﬁcient beta t Sig.
F 12.542 Caspase 3 Differentiation −2.970 1.324 −0.196 −2.243 0.027
sig. 0.0001 Bcl-2 9.967 1.759 .0486 5.665 0.000
Constant −8.376 3.075 −2.724 0.008
natural history, since, as a whole, UTUC is more invasive and less differentiated than bladder cancer [24,
25].
In regions associated with BEN, which is today considered an entity of aristolochic acid nephropathy,
a worldwide disease [26, 27], UTUC, is up to 100 times more frequent than in nonendemic areas [1]. The
comparative study between patients from endemic and nonendemic areas, which included tumor grade,
stage, pattern of invasion, growth pattern, lymphovascular invasion, necrosis, and metaplastic changes of
UTUC, concluded that growth pattern discriminated these groups of tumors [28]. Further studies implied
that the genetic aberrations and molecular pathways included in cancer evolution are also different [11, 13,
29].
Urothelial cancer may resist programmed cell death with altered expression of both antiapoptotic
and proapoptotic proteins [14, 15]. Survivin, a unique member of the inhibitor of apoptosis proteins (IAP)
family, is highly expressed during normal tissue development but is absent in most terminally differentiated
cells of adult tissues [30]. Survivin becomes prominently reexpressed in variety of cancers [25, 31]. Its
overexpression inhibits extrinsic and intrinsic pathways of apoptosis in tumor cells [15, 32] and accelerates
their mitotic activity [33]. In patients with UTUC, Shariat et al. recognized positive expression of Survivin
in 12.7% of samples, a granular pattern being apparent within the cytoplasm of tumor cells [34]. In this
research, we analysed the nuclear Survivin staining, according to the conclusions of recently published
studies related to TCC [20, 35]. We found that 59,1% of analyzed BEN-associated carcinomas had altered
Survivin expression in contrast to 47,5% immunopositivity in control tumors. However, this difference was
not statistically signiﬁcant.
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In addition, present study demonstrated that Survivin expression was signiﬁcantly higher in BEN
tumors with high grade and solid growth than in control tumors with the same morphological features.
Although some authors suggested that Survivin expression did not correlate with clinicopathologic ﬁndings
in UTUC [36, 37], recent studies of bladder cancer demonstrated that nuclear positive staining correlated
strongly with increased grade, stage, and the probability of tumor recurrence [35, 38]. In terms of clinical
application, Survivin is regarded one of the most promising prognostic biomarkers for TCC [34].
Another famous antiapoptotic protein, Bcl-2, prevents Bax/Bak interaction, subsequent cytochrome
c release, and caspase activation [39]. Aberrant Bcl-2 staining expressed signiﬁcant association with tumor
grade and tumor invasiveness in the TCC of the bladder [37, 40]. In previous investigations of UTUC, Bcl-2
only signiﬁcantly correlated with tumor stage [41]. Nevertheless, our results did not reveal any signiﬁcant
association of altered Bcl-2 expression and pathological features of the investigated tumors.
Within the intrinsic apoptotic pathway, in response to proapoptotic stimuli, Bax protein effects
the permeabilization of the outer mitochondrial membrane, allowing cytochrome c to escape into the
cytosol where it can induce caspase activation and cell death [42]. Our study demonstrated that Bax
immunopositivity was signiﬁcantly associated with the tumor stage, which is in agreement with recently
published data related to bladder cancer [40]. Altered expression of Bax was signiﬁcantly more frequent
in the advanced stage tumors. Moreover, Bax expression correlated with caspase 3 index, supporting a
proapoptotic role of this protein. Regression analysis, which included all investigated apoptotic markers,
group, pathological characteristics, gender, and localization, detected Bax as the speciﬁc indicator of UTUC
arising in BEN regions. BEN-related UTUC was signiﬁcantly associated with reduced immunopositivity of
Bax compared to control tumors. Bax aberrant staining was less frequent in BEN tumors with high grade,
high stage, with necrosis, or without metaplastic change than in control tumors with the same morphological
characteristics, thus, implying the decreased proapoptotic activity in tumors arising in endemic regions.
Investigation of Fas receptor expression also showed signiﬁcant differences between BEN and
controltumorswithdesignatedfeatures.AberrantFasexpressionwasobservedin52.3%ofBENUTUCand
36.1% control tumors but without statistically signiﬁcant difference between these two groups. Although
Fas (CD95/Apo1) represents a typical death receptor from tumor necrosis factor superfamily [43]a n di s
located in the cell membrane, Fas immunoreactivity demonstrated predominantly cytoplasmic staining
pattern, without clear membranous expression. BEN tumors had signiﬁcantly higher diffuse cytoplasmic
expression of Fas receptor which was detected in nonmetaplastic BEN-associated UTUC. Regression
analysis detected Fas as the speciﬁc indicator of localization and metaplastic change in UTUC. BEN-related
UTUC with localization in ureter was signiﬁcantly associated with altered Fas expression. Interestingly,
recent data suggest that the expression of Fas receptor does not necessarily predict susceptibility to
apoptosis and may not correlate with its biological function [44]. In fact, the retention of Fas protein
within the cytoplasm may represent a mechanism by which malignant cells evade Fas-mediated apoptosis
[19].
Two major apoptotic pathways, a stress-induced and a death receptor-mediated pathway, both induce
apoptosis via activation of effector caspases, where caspase 3 is generally considered to be the primary
executioner of apoptosis [22]. Cleaved caspase 3 antibody detects only large fragment (17/19kDa) of
activated caspase 3; thus, the immunopositivity could clearly speciﬁcally distinguish cells in apoptosis (cells
showing typical apoptotic morphology, outside the areas of necrosis) from normal cells [45]. Active caspase
3 has been found to be signiﬁcantly associated with unfavorable histological parameters such as high grade
and advanced stage of bladder tumours [40]. In a study that included 112 patients with TCC of upper urinary
tract, altered expression of caspase 3 was signiﬁcantly associated with pathologic grade and tumor stage
[36]. In this investigation, cleaved caspase 3 immunoreactivity was also signiﬁcantly associated with tumor
differentiation. Previously, it was found that absence of caspase 3 activation was related to the expression of
antiapoptotic proteins (Bcl-2, IAP) [46]. Interestingly, the results of linear regression analysis demonstrated
signiﬁcant association of caspase 3 index and Bcl-2 expression in investigated tumors. Proteolytic activation
of caspase 3 may be blocked by the overexpression of Bcl-2, but caspase 3 is able to reverse the function
of Bcl-2 by cleaving it to a truncated, proapoptotic form [19]. This may at least partially contribute to
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explanation of our ﬁndings. Although cleaved caspase 3 index had higher value in UTUC arising in BEN
regions than in control tumors, this difference was not statistically signiﬁcant.
Failure to enter apoptosis allows transformed cells to continue further cell divisions and acquire
further mutations [46]. In a hypoxic environment that does not support cell Survival, apoptosis is also
involved in selective growth and progression of the least demanding subclones with higher malignant
potential. Present investigation has revealed that immunoreactivity of proapoptotic protein Bax is less
frequently altered in UTUC arising in endemic regions than in control tumors. However, the difference
in cleaved caspase 3 activity between the investigated groups was not statistically signiﬁcant. This might
imply that decreased expression of Bax in BEN tumors compared to control tumors does not necessarily
result in the decrease of effective apoptosis.
In conclusion, this investigation of multiple apoptosis-related markers identiﬁes Bax as speciﬁc
indicator of BEN-associated UTUC. Our ﬁndings suggest that decreased proapoptotic activity of Bax
together with higher Survivin expression may indicate speciﬁc disturbances of intrinsic apoptotic pathway
in UTUC arising in endemic areas.
The major limitation of this study is a relatively small number of BEN tumors; however, this is a rare
disease, especially in the last ten years.
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